Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Interest Expenses (2022 - 2025)

BioXcel Therapeutics has reported Interest Expenses over the past 4 years, most recently at $3.9 million for Q4 2025.

  • Quarterly results put Interest Expenses at $3.9 million for Q4 2025, down 8.18% from a year ago — trailing twelve months through Dec 2025 was $15.8 million (up 2.59% YoY), and the annual figure for FY2025 was $15.3 million, up 1.34%.
  • Interest Expenses for Q4 2025 was $3.9 million at BioXcel Therapeutics, down from $4.4 million in the prior quarter.
  • Over the last five years, Interest Expenses for BTAI hit a ceiling of $4.4 million in Q3 2025 and a floor of $7000.0 in Q1 2022.
  • Median Interest Expenses over the past 4 years was $3.6 million (2024), compared with a mean of $3.1 million.
  • Peak annual rise in Interest Expenses hit 43242.86% in 2023, while the deepest fall reached 12.11% in 2023.
  • BioXcel Therapeutics' Interest Expenses stood at $2.1 million in 2022, then increased by 0.1% to $2.1 million in 2023, then skyrocketed by 107.42% to $4.3 million in 2024, then decreased by 8.18% to $3.9 million in 2025.
  • The last three reported values for Interest Expenses were $3.9 million (Q4 2025), $4.4 million (Q3 2025), and $3.8 million (Q2 2025) per Business Quant data.